Koseki N, Araie M, Yamagami J, Shirato S, Yamamoto S
Department of Ophthalmology, University of Tokyo School of Medicine, Japan.
J Glaucoma. 1999 Apr;8(2):117-23.
To prospectively study the effect of oral brovincamine, a relatively selective cerebral vasodilator, on further deterioration of visual field in patients with normal-tension glaucoma (NTG) with low-normal intraocular pressure (IOP).
Fifty-two patients with NTG (average age 57.7 years) with an IOP that was consistently less than 15 mmHg were randomly assigned to receive oral brovincamine (20 mg three times daily) or to an untreated control group. The groups were prospectively followed for 2 years with visual field examinations every 4 months, using the 30-2 Humphrey perimeter program. Changes in mean deviation (MD), corrected pattern standard deviation (CPSD), and total deviation (TD) at 74 test points were analyzed using regression analysis with linear mixed model. Data from one eye without media opacity of each subject were analyzed.
There were no differences between groups in age; sex distribution; refraction; blood pressure; baseline IOP; MD, CPSD, or TD at each point. Changes in MD (standard error [SE]) during the study period were -0.778 (0.178) and -0.071 (0.195) dB/year in the control and brovincamine groups, respectively; change in the control group was significantly more negative than in the brovincamine group. Change in CPSD (SE) was 0.032 (0.015) and 0.004 (0.016) dB/year in the control and brovincamine groups, respectively. Change in the control group was significantly positive, but the intergroup difference was not significant. Change in TD was significantly negative at six test points in the control group, whereas no points showed a significant trend in the brovincamine group; the intergroup difference was significant. The average IOP was 13.2 mmHg and 13.1 mmHg in the control and brovincamine groups, respectively, and there was no significant intergroup difference.
Oral brovincamine may retard further visual field deterioration in patients with NTG who have low-normal IOP.
前瞻性研究口服溴长春胺（一种相对选择性的脑血管扩张剂）对眼压正常（NTG）且眼压略低于正常范围的患者视野进一步恶化的影响。
52例NTG患者（平均年龄57.7岁），眼压持续低于15 mmHg，随机分为口服溴长春胺组（20 mg，每日3次）或未治疗的对照组。对两组进行前瞻性随访2年，每4个月使用30-2 Humphrey视野计程序进行视野检查。使用线性混合模型的回归分析，分析74个测试点的平均偏差（MD）、校正模式标准差（CPSD）和总偏差（TD）的变化。分析每个受试者一只无介质混浊眼睛的数据。
两组在年龄、性别分布、屈光、血压、基线眼压、各点的MD、CPSD或TD方面无差异。研究期间，对照组和溴长春胺组MD（标准误[SE]）的变化分别为-0.778（0.178）和-0.071（0.195）dB/年；对照组的变化明显比溴长春胺组更负。对照组和溴长春胺组CPSD（SE）的变化分别为0.032（0.015）和0.004（0.016）dB/年。对照组的变化明显为正，但组间差异不显著。对照组在6个测试点TD的变化明显为负，而溴长春胺组无点显示出明显趋势；组间差异显著。对照组和溴长春胺组的平均眼压分别为13.2 mmHg和13.1 mmHg，组间无显著差异。
口服溴长春胺可能延缓眼压略低于正常范围的NTG患者视野的进一步恶化。
